
LITERATURA

1. Alexopoulos GS, Katz IR, Reynolds CF, Carpenter D, Docherty JP. Pharmacotherapy of depressive disorders in older patients. Comprehensive NeuroScience, Inc., New York 2001, 76 s.
2. Auriacombe S, Pere JJ, Loria-Kanza, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Current Medical research and opinion vol 2002;18; 3: 129-138.
3. Bareš M. Léčba depresivní poruchy v pozdním věku. Klin. Farmakol. Farm 2004;18:38-44.
4. Basire S. Psychotropic drug directory 2003/04. Fivepin Publishing, Ltd., Salisbury 2003, 416 s.
5. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Progress in Cardiovascular Diseases 2001;43 Suppl. 1:1-45.
6. Blazer DG, Steffens CD, Busse EW. Textbook of geriatric psychiatry. American Psychiatric Publishing, Inc., Washington, DC 2004, 568 s.
7. Bryant J, Clegg A, Nicholson T, et al. Clinical and cost-effectiveness of donepezil, rivastigmin and galantamin for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001;5:1-137.
8. Burns A, Craig S, Lawlor B. Assesment scales in old age. Psychiat. Martin Dunitz, London 1999, 302 p.
9. Corey-Bloom J, Anand R, Veach J, for the ENA-713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychofarmacol 1998;1:55-65.
10. Cummings JL. The Neuropsychiatry of Alzheimer's disease and related dementia. Martin Dunitz, London 2003, 312 p.
11. Doody RS, Stevens JC, Beck C et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurol. Neurol 2001;56:1154-1166.
12. Gauthier S. Alzheimer's disease. Martin Dunitz, London 2001, 386 p.

13. Gelder MG, Lopez-Ibor JJ, Anreasen NC. New Oxford textbook of psychiatry. Oxford University Press, New York 2003, 2432 s.
14. Giacobini E. Cholinesterases and cholinesterase inhibitors. Martin Dunitz 2000, 270 p.
15. Goodwin G, Sachs G. Bipolar disorder. Health Press Ltd., Abingdon 2004, 100 s.
16. Goodyer IM. Unipolar depression. Oxford University Press, Oxford 2003, 212 s.
17. Grossberg GT, Stehelin HB, Messina JC, Anand R, Veach J. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twentytwo classes of medications. *Int J Geriatr Psychiat* 2002;15:242-247.
18. Helmchen H, Lauter H. Diagnostic problems in geriatric psychiatry. In: Henn, F, Sartorius, N, Helmchen, H, Lauter, H.: Contemporary psychiatry. Springer, New York 2001, vol 3. pp. 117-128.
19. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. *UCP Supplement* June 2002;12:45-63.
20. Jacobson SA, Pies RW, Greenblatt DJ. Handbook of geriatric psychopharmacology. American Psychiatric Publishing, Inc. Washington, DC 2002, 496 p.
21. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. *Clin Pharmacokinet* 2002; 41 [10]: 719-739.
22. Jiráček R, Koukolík F. Demence. Neurobiologie, klinický obraz, terapie. Galén, Praha 2004, 336 s.
23. Jiráček R, et al. Demence. Maxdorf, Praha 1999, 226 s.
24. Kennedy SH, Lam RW, Nutt DJ, Thase ME. Treating depression effectively. Applying clinical guidelines. Martin Dunitz, London 2004, 154 s.
25. Maj M, Akiskal HS, Lopez-Ibor JJ, Sartorius N. Bipolar disorder. John Wiley and Sons Ltd., Chichester 2003, 524 s.
26. Maj M, Sartorius N. Dementia. John Wiley and Sons Ltd., Chichester 2002, 398 s.
27. Mesulam M, Guillozet al. Shaw P, et al. Widely spread butyrylcholinesterase can hydrolyse acetylcholine in the normal and Alzheimer brain. *Neurobiol Dis* 2002;9:88-93.
28. Murray CJL, Lopez AD. The global burden of disease. Cambridge, Harvard University Press 1996.
29. Muller WE, Forstl H. Pharmacological and nonpharmacological approaches to the treatment of dementia. In: Henn, Sartorius, Helmchen, Lauter: Contemporary psychiatry. New York 2001;2:35-46.
30. Nordberg A, Darreh-Shori T, Svensson A et al. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment. *J Neurol Sci* 2001;187(Suppl 1):P0144.
31. Pidrman V. Demence - základní diferenciální diagnostika a farmakoterapie. *Postgraduální medicína, příloha* 2004;6[3], s. 30-35.
32. Pidrman V. Deprese seniorů. Maxdorf, Praha 2003, 60 s.
33. Pidrman V, Bouček J, Kryl M. Deprese v interní medicíně. PCP, Praha 2003, 46 s.

34. Pidrman V. Farmakoterapie demence. In: Růžička, E et al.: Diferenciální diagnostika a léčba demencí. Galén, Praha 2003, s. 113–136.
35. Pidrman V. Deprese a kardiovaskulární onemocnění. Maxdorf, Praha 2004.
36. Qizilbash N, Schneider LS, Chui H, Tariot P et al. Evidence-based dementia practice. Blackwell Publ. Oxford 2003, 894 p.
37. Růžička E, et al. Diferenciální diagnostika a léčba demencí. Galén, Praha 2003, 176 p.
38. Raskind MA, Peskind ER, Wessel T et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with 6-month extension. The galantamine USA-1 Study Group. *Neurol* 2000;54: 2261–2268.
39. Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. *BMJ* 1999;318:633–638.
40. Reuben BD, Herr KA, Pacala JT et al. Geriatrics at your fingertips. Blackwell Publishing, Inc., Malden 2003, 240 p.
41. Siek GC, Katz LS, Fishman EB et al. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer's disease brain. *Biol Psychiat* 1990;27:573–580.
42. Sheikh JI, Cassidy EL, Doraiswamy PM et al. Efficacy, safety and tolerability of patients with late-life depression and comorbid medical illness. *JAGA* 2004;52:86–92.
43. Shiloh R, Nutt D, Weizman A. Atlas of psychiatric pharmacotherapy. Martin Dunitz, London 2000, 236 p.
44. Schaltberg AF, Cole JO, DeBatista C. Manual of clinical psychopharmacology. American Psychiatric Publishing, Inc. Washington, DC 2003, 700 p.
45. Smolík P. Duševní a behaviorální poruchy. Průvodce klasifikací, nástin nozologie, diagnostika. Maxdorf, Praha 1996, 504 s.
46. Sobotka L. Basics in Clinical Nutrition. Galén, Praha 2000, 300 p.
47. Stahl MS. Essential psychopharmacology. Neuroscientific basis and practical applications. Cambridge University Press, Cambridge 2002, 602 s.
48. Stein DJ, Hollander E. Textbook of anxiety disorders. American Psychiatric Publishing, Inc., Washington, DC 2002, 516 s.
49. Tasman A, Kay J, Lieberman JA. Pocket companion to accompany psychiatry. Philadelphia, W B. Saunders comp 1998, 632 p.
50. Taylor D, Paton C, Kervin R. 2003 prescribing guidelines. 7th edition. Martin Dunitz, London, 2003, 272 s.
51. Těšínský P, Ryšavý Z. Doporučené postupy v enterální výživě. *Klinická výživa a intenzivní metabolická péče* 2001;2 [1]: 27–31.
52. Vellas B, Inglis F, Potkin S et al. Interim results from an international clinical trial with rivastigmine evaluating a 2-week titration rate in mild to severe Alzheimer's disease patients. *Int J Geriatr Psychopharmacol* 1998;1:140–144.
53. Weinstock M. Selectivity of cholinesterase inhibition. *CNS Drugs* 1999;12:307–323.
54. Winblad B. Memantine and Alzheimer disease. Science Press Ltd, London 2003, 64 p.

55. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multi-centre randomized controlled trial. Galantamine International-1 Study Group. *BMJ* 2000;321:1445-1449.
56. Wilkinson DG, Passmore P, Smith R et al. Comparison of the tolerability, ease of use and efficacy of donepezil and Exelon in Alzheimer's disease patients: a 12-week multinational study. Presented at the 53rd Annual Meeting of the American Academy of Neurol, Philadelphia, Pennsylvania 5-12 May 2001.
57. Wolkowitz OM, Rothschild AJ. *Psychoneuroendocrinology*. American Psychiatric Publishing, Inc., Washington, DC 2003, 588 s.
58. Zurag EG. New treatments of Alzheimer's disease: a review. *A Drug Benefit Trends* 2001;13:27-40.
59. Behavioral and psychological symptoms of dementia. Educational pack. International Psychogeriatric Association, Belgium 2003, 34 p.
60. Practice guidelines for treatment of psychiatric disorders. Compendium 2002. American Psychiatric Association, Washington DC 2002, 914 s.
61. Quick reference to the AP. A practice guidelines for treatment of psychiatric disorders. Compendium 2002. American Psychiatric Association, Washington DC 2002, 195 s.
62. Unnecessary drugs in the elderly (OBRA). Health Care Consortium, Inc. Lancaster 1992-2002, 82 p.
63. Brodaty H, Green AL, Koschera A. Meta-Analysis of Psychosocial Interventions for Caregivers of People with Dementia. *J American Geriatric Society* 2003;51, 1-8.
64. Doody RS, Stevens JC et al. Practice parameter: Management of dementia (an evidence-based review). *Neurol* 2001;56:1154-1166.
65. Hátlová B, Suchá J. Kinezioterapie demenci. v tisku.
66. Holmerová I. Problematika pečujících rodin, možnosti pomoci a podpory. *Česká geriatrická revue* 2/2003 s. 33-37.
67. Holmerová I, Suchá J. Reminiscenční terapie. *Praktický lékař* 2003;83, č.5, s. 295-297.
68. Veleta P, Holmerová I. Úvod do taneční terapie pro seniory. Česká alzheimerská společnost Praha 2003, 66 s.